Skip header and navigation

Refine By

121 records – page 1 of 13.

Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

https://arctichealth.org/en/permalink/ahliterature13711
Source
Scand J Rheumatol. 2005 Sep-Oct;34(5):353-8
Publication Type
Article
Author
M C Wick
S. Ernestam
S. Lindblad
J. Bratt
L. Klareskog
R F van Vollenhoven
Author Affiliation
Department of Rheumatology, Karolinska University Hospital, Solna, Sweden.
Source
Scand J Rheumatol. 2005 Sep-Oct;34(5):353-8
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Psoriatic - drug therapy
Arthritis, Rheumatoid - drug therapy
Drug resistance
Humans
Immunoglobulin G - therapeutic use
Middle Aged
Receptors, Tumor Necrosis Factor - therapeutic use
Registries
Research Support, Non-U.S. Gov't
Sweden
Treatment Failure
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Abstract
OBJECTIVES: To determine whether the tumour necrosis factor-alpha (TNF-alpha) antagonist adalimumab (Humira) can be efficacious after secondary loss of efficacy (i.e. loss of clinical response in patients who had initially demonstrated clinical response) to infliximab (Remicade) or etanercept (Enbrel). PATIENTS AND METHODS: We studied 36 patients from the Stockholm TNF-alpha follow-up registry (STURE) who received adalimumab after secondary loss of efficacy to infliximab (group A, n = 27) or etanercept (group B, n = 9), and 26 patients who were started on adalimumab as the first TNF-alpha antagonist (group C). RESULTS: In group A, the baseline disease activity score 28 (DAS28) at infliximab institution was 5.5+/-0.2. During infliximab treatment, the mean best DAS28 was 3.7+/-0.2 (p
PubMed ID
16234182 View in PubMed
Less detail

Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.

https://arctichealth.org/en/permalink/ahliterature21930
Source
Cancer Res. 1997 Oct 15;57(20):4530-6
Publication Type
Article
Date
Oct-15-1997
Author
H O Sjögren
M. Isaksson
D. Willner
I. Hellström
K E Hellström
P A Trail
Author Affiliation
Department of Cell and Molecular Biology, University of Lund, Sweden.
Source
Cancer Res. 1997 Oct 15;57(20):4530-6
Date
Oct-15-1997
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - pathology - secondary
Animals
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Colonic Neoplasms - drug therapy - pathology
Doxorubicin - therapeutic use
Female
Humans
Immunotoxins - therapeutic use
Liver Neoplasms - drug therapy - pathology - secondary
Mice
Mice, Nude
Rats
Rats, Inbred BN
Research Support, Non-U.S. Gov't
Transplantation, Heterologous
Transplantation, Isogeneic
Tumor Cells, Cultured
Abstract
The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone bond to DOX and a thioether bond to the monoclonal antibody. The resulting conjugate, termed BR96-DOX, binds to a tumor-associated Lewis(y) antigen that is abundantly expressed on the surface of human carcinoma cells. BR96-DOX binds to RCA, a human colon carcinoma cell line, and BN7005, a transplantable colon carcinoma induced in a Brown Norway (BN) rat by 1,2-dimethyl-hydrazine. BR96-DOX produces cures of established s.c. RCA human colon carcinomas in athymic mice and rats. BR96-DOX also cured both s.c. and intrahepatic BN7005 tumors in immunocompetent BN rats. Unconjugated DOX, given at its maximum tolerated dose, and matching doses of nonbinding IgG-DOX conjugate were not active against RCA or BN7005 carcinomas. An anticonjugate antibody response was produced in BN rats treated with BR96-DOX. However, this could be largely prevented by administering the immunosuppressive drug deoxyspergualin. These results confirm the concept of antibody-directed therapy in models in which the targeted antigen is expressed both in normal tissues and tumors. The findings in BN7005 further demonstrate efficacy of BR96-DOX therapy in a model in which the tumor is syngeneic and the host is immunocompetent.
PubMed ID
9377565 View in PubMed
Less detail

Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.

https://arctichealth.org/en/permalink/ahliterature30061
Source
Acta Paediatr. 2004 Nov;93(11):1470-3
Publication Type
Article
Date
Nov-2004
Author
L. Navér
M. Eriksson
U. Ewald
A. Linde
M. Lindroth
J. Schollin
Author Affiliation
Department of Clinical Science, Division of Paediatrics, Karolinska University Hospital, Huddinge, Sweden. lars.naver@klinvet.ki.se
Source
Acta Paediatr. 2004 Nov;93(11):1470-3
Date
Nov-2004
Language
English
Publication Type
Article
Keywords
Antibodies, Monoclonal - therapeutic use
Antiviral agents - therapeutic use
Hospitalization - statistics & numerical data
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - epidemiology - prevention & control
Practice Guidelines
Prospective Studies
Respiratory Syncytial Virus Infections - epidemiology - prevention & control
Sweden - epidemiology
Abstract
AIM: Palivizumab (Synagis) was registered in Sweden in 1999 for prophylaxis against respiratory syncytial virus (RSV) in premature infants. The high costs and the limited knowledge of the efficacy of this substance have led to debate about how and when it should be used. National guidelines for the use of palivizumab in Sweden were constructed in the year 2000. The aim of this study was to evaluate the guidelines. METHODS: A nation-wide prospective study was conducted during the two RSV seasons of the years 2000-2002. The paediatric departments in Sweden reported the use of palivizumab, the indication for its use, and the number of infants born preterm before 36 wk of gestation and less than 2 y old who were admitted to hospital for RSV infection. RESULTS: During the two seasons, 218 (3.8%) children who were born before 36 wk of gestation, and 97 (5.4%) who were born before 33 wk, were hospitalized because of RSV infection. Five children were treated with mechanical ventilation. No death caused by RSV was reported. A total of 390 children were treated with palivizumab, and 16 (4.1%) of those who received prophylactic treatment were admitted to hospital with RSV infection. CONCLUSION: We consider the comparatively restrictive Swedish recommendations to be safe and recommend that palivizumab should also be used very restrictively in the future. In our opinion, palivizumab in preterm children could be recommended only for those with chronic lung disease younger than 1 y of age, and with active treatment for their disease.
PubMed ID
15513574 View in PubMed
Less detail

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

https://arctichealth.org/en/permalink/ahliterature265097
Source
Ann Rheum Dis. 2015 Jun;74(6):1212-7
Publication Type
Article
Date
Jun-2015
Author
Elizabeth V Arkema
Jerker Jonsson
Eva Baecklund
Judith Bruchfeld
Nils Feltelius
Johan Askling
Source
Ann Rheum Dis. 2015 Jun;74(6):1212-7
Date
Jun-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy - epidemiology
Biological Products - therapeutic use
Case-Control Studies
Cohort Studies
Female
Humans
Immunoglobulin G - therapeutic use
Male
Middle Aged
Proportional Hazards Models
Receptors, Tumor Necrosis Factor - therapeutic use
Risk factors
Sweden - epidemiology
Tuberculosis - epidemiology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Abstract
To estimate the risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) both with and without exposure to biological therapy and to directly compare the risks between therapies.
Data from the Swedish National Population Registers, Tuberculosis Register and the Swedish Biologics Register were used to conduct a prospective population-based national cohort study (2002-2011). We estimated the rate of incident TB in the general population and in a cohort of biological-naïve and biological-exposed patients diagnosed with RA. Cox models were used to estimate HRs with particular attention to risks by calendar and follow-up time and individual biologics.
Compared to the general population, RA patients not exposed to biologicals had a fourfold increased risk of TB (HR 4.2; 95% CI 2.7 to 6.7), which did not decline over calendar time. In contrast, the risk of TB in the biological-exposed RA population decreased since 2002 compared with biological-naïve; from HR=7.9 (95% CI 3.3 to 18.9) in 2002-2006 to HR=2.4 (95% CI 0.9 to 6.1) in 2007-2011. The HRs for most recent exposure to adalimumab and infliximab compared with etanercept were 3.1 (95% CI 0.8 to 12.5) and 2.7 (95% CI 0.7 to 10.9), respectively, and the HR for etanercept compared with biological-naïve RA was 1.7 (95% CI 0.6 to 4.6).
In the past decade, the risk of TB has decreased among biological-exposed RA patients but remains higher than in biological-naïve RA patients. Most cases of TB in RA occur in biological-naïve RA patients, underscoring the elevated risk also in these patients.
PubMed ID
24608401 View in PubMed
Less detail
Source
Tidsskr Nor Laegeforen. 2007 Aug 9;127(15):1961-2
Publication Type
Article
Date
Aug-9-2007
Author
Trygve Holmøy
Elisabeth Gulowsen Celius
Author Affiliation
Nevrologisk avdeling Ullevål universitetssykehus.
Source
Tidsskr Nor Laegeforen. 2007 Aug 9;127(15):1961-2
Date
Aug-9-2007
Language
Norwegian
Publication Type
Article
Keywords
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Drug Information Services
Humans
Multiple Sclerosis - drug therapy
Norway
Practice Guidelines as Topic
PubMed ID
17700745 View in PubMed
Less detail

Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents.

https://arctichealth.org/en/permalink/ahliterature163347
Source
Biotechnol J. 2007 Jul;2(7):863-70
Publication Type
Article
Date
Jul-2007
Author
Pavel K Ivanov
Dmitry Y Blokhin
Evgeny F Chmutin
Anatoly S Grinevich
Dmitry V Perlin
Alexander S Sokolsky
Raisa I Yakubovskaya
Anatoly Y Baryshnikov
Author Affiliation
Research and Manufacturing Center Medbiospectr Ltd, Moscow, Russia.
Source
Biotechnol J. 2007 Jul;2(7):863-70
Date
Jul-2007
Language
English
Publication Type
Article
Keywords
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Clinical Trials as Topic - trends
Humans
Immunotherapy - trends
Neoplasms - drug therapy
Russia
Abstract
The N. Blokhin National Cancer Research Center is one of the few Russian scientific institutions in which hybridoma technology of monoclonal antibody (mAb) production has been successfully established. Using this technology, several dozens of mAbs to various antigens of human leukocytes have been elaborated. These mAbs are widely used for immune status evaluation and for differential diagnostics of leukemias. Two mAbs were used to develop therapeutic drugs. Imuteran is a pharmaceutical form of mAb ICO-25 against a mucin-like antigen of human milk fat globules and proposed for treatment of epithelial cell-originating cancers (breast, intestinal, ovarian, lung cancer, etc.). ThePhase II clinical study of this agent is now nearly completed, and preliminary results suggest Imuteran to be a promising anticancer agent with tumor-stabilizing activity, but patients should be carefully monitored for signs of allergic reactions. mAb ICO-90 against the CD3 antigen of human T lymphocytes was used to develop the therapeutic agent Atemonate proposed for treatment of acute transplant rejection. At present, the Phase II clinical study of this agent is over, and the results confirm the drug safety and efficacy for this indication. The drug is being registered at the Ministry of Healthcare and Social Development, and transfer to serial production is expected shortly.
PubMed ID
17526052 View in PubMed
Less detail

Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.

https://arctichealth.org/en/permalink/ahliterature166927
Source
Pediatr Pulmonol. 2006 Dec;41(12):1167-74
Publication Type
Article
Date
Dec-2006
Author
Ian Mitchell
Suzanne Tough
Lynne Gillis
Carina Majaesic
Author Affiliation
Department of Paediatrics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Source
Pediatr Pulmonol. 2006 Dec;41(12):1167-74
Date
Dec-2006
Language
English
Publication Type
Article
Keywords
Alberta - epidemiology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Female
Follow-Up Studies
Hospitalization - statistics & numerical data
Humans
Infant, Newborn
Male
Prevalence
Respiratory Syncytial Virus Infections - epidemiology - prevention & control
Respiratory Syncytial Virus, Human
Retrospective Studies
Risk factors
Seasons
Treatment Outcome
Abstract
A population-based study of the impact of palivizumab on confirmed Respiratory Syncytial Virus (RSV) hospitalizations over a 7-year period within and between two similar health regions . Clinicians in Calgary implemented palivizumab prophylaxis for high-risk infants during the last four RSV seasons; clinicians in Edmonton did not. The two cities are part of a unified health care system and similar sociodemographics. Infants
PubMed ID
17058279 View in PubMed
Less detail

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.

https://arctichealth.org/en/permalink/ahliterature175543
Source
Scand J Rheumatol. 2004;33(6):423-7
Publication Type
Article
Date
2004
Author
R F van Vollenhoven
I. Gunnarsson
E. Welin-Henriksson
B. Sundelin
A. Osterborg
S H Jacobson
L. Klareskog
Author Affiliation
Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden. ronald.vanvollenhoven@ks.se
Source
Scand J Rheumatol. 2004;33(6):423-7
Date
2004
Language
English
Publication Type
Article
Keywords
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - therapeutic use
Biopsy, Needle
Cyclophosphamide - therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Follow-Up Studies
Humans
Immunohistochemistry
Kidney Function Tests
Lupus Nephritis - drug therapy - pathology
Risk assessment
Severity of Illness Index
Sweden
Treatment Outcome
Abstract
The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis.
Two female patients with biopsy-confirmed severe and active SLE nephritis despite treatment with cyclophosphamide (CyX) were given four rituximab infusions plus two additional CyX infusions.
Both patients tolerated the treatment well and SLE activity improved. On repeat kidney biopsy after the combined treatment, Patient 1 showed a profound reduction of nephritis activity, and she was maintained on low-dose prednisolone only. A repeat biopsy after 1 year confirmed the sustained reduction of lupus nephritis activity. In Patient 2, rebiopsy after combined treatment also showed a significant reduction in disease activity.
These cases provide histopathological documentation of a significant treatment benefit from rituximab plus CyX in two patients refractory to CyX alone. This combination is being explored further as salvage therapy for such CyX-resistant patients.
PubMed ID
15794203 View in PubMed
Less detail
Source
Can Fam Physician. 2008 May;54(5):742-3
Publication Type
Article
Date
May-2008
Author
Graham Worrall
Author Affiliation
Family Medicine at Memorial University of Newfoundland in St John's. gworrall@mun.ca
Source
Can Fam Physician. 2008 May;54(5):742-3
Date
May-2008
Language
English
Publication Type
Article
Keywords
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antiviral agents - therapeutic use
Bronchiolitis - diagnosis - epidemiology - therapy - virology
Canada - epidemiology
Hospitalization
Humans
Infant
Respiratory Syncytial Virus Infections - complications
Notes
Cites: Cochrane Database Syst Rev. 2004;(1):CD00312314974006
Cites: Cochrane Database Syst Rev. 2004;(3):CD00487815266547
Cites: Cochrane Database Syst Rev. 2000;(2):CD00126610796626
Cites: Cochrane Database Syst Rev. 2008;(1):CD00487818254063
Cites: Pediatrics. 2000 Apr;105(4):E4410742365
Cites: Cochrane Database Syst Rev. 2005;(3):CD00127916034861
PubMed ID
18474710 View in PubMed
Less detail

121 records – page 1 of 13.